Real-Time Margin Measurement
for Precision Cancer Surgery
Navigation Sciences is developing the NaviSci™ system to address the growing need to locate and remove lung and other soft tissue cancers.
- Reduce early-stage cancer recurrence risk
- Conserve lung function
- Improve surgical workflow
- Shorten hospital length of stay
NaviSci’s first application is in early-stage lung cancer, where there are more than 76,000 new cases each year in the U.S.; the number is growing annually due to increasing adoption of CT x-ray screening.
Overall, there are approximately 450,000 soft tissue cancer diagnoses annually in the U.S. where NaviSci has potential application.
Navigation Sciences Announces a $3 Million First Close of $5 Million Series B Equity Financing Read more
Navigation updates in Q2 2023 newsletter Read more
Navigation updates in Q1 2023 newsletter Read more
Lung-Sparing Surgery Effective for Some with Early-Stage Lung Cancer Read more
Navigation updates in Q4 2022 newsletter Read more
Navigation updates in Q3 2022 newsletter Read more
NaviSci is based on technology developed by the company’s co-founders, leaders in thoracic surgery and advanced surgical navigation technology, Raphael Bueno, M.D., Chief, Thoracic Surgery, and Jayender Jagadeesan, Ph.D., Associate Professor of Radiology both at Brigham & Women’s Hospital and Harvard Medical School. View our leadership team